• Sat. Apr 20th, 2024

Nexalin Technology’s Gen-2 tACS Device Proves Effective in Reducing Pain in Veteran Patients with Mild Traumatic Brain Injury in Clinical Trial

BySamantha Jones

Apr 4, 2024
Gen-2 tACS device shows promising results in clinical study conducted by Nexalin Technology

Mark White, CEO of Nexalin Technology, recently discussed the positive outcomes of a clinical trial involving their Gen-2 tACS device for pain reduction in veteran patients with Mild Traumatic Brain Injury (mTBI). The trial took place at The University of California, San Diego, in collaboration with the United States Department of Veterans Affairs San Diego Healthcare System, as well as various departments at UC San Diego.

The study was conducted over an eight-week period and involved two groups: an active tACS group and a sham tACS group. Twenty-four veteran patients with mTBI received twelve treatment sessions over four weeks, followed by a four-week observation period to analyze outcomes.

The results of this study are especially notable given the extensive market potential for therapies addressing traumatic brain injuries. According to Global Market Insights, the Traumatic Brain Injuries Assessment Market is forecasted to exceed $7.2 billion by 2032. Nexalin’s innovative approach shows promise in meeting the needs of individuals coping with mTBI, potentially enhancing their quality of life and offering hope for more effective treatment options in the future.

By Samantha Jones

As a dedicated content writer at newszxcv.com, I bring a passion for storytelling and a keen eye for detail to every piece I create. With a background in journalism and a love for crafting engaging narratives, I strive to deliver informative and captivating content that resonates with our readers. Whether I'm covering breaking news or delving into in-depth features, my goal is to inform, entertain, and inspire through the power of words. Join me on this journey as we explore the ever-evolving world of news together.

Leave a Reply